Amneal Pharmaceuticals, Inc. Profile Avatar - Palmy Investing

Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segm…

Drug Manufacturers - Specialty & Generic
US, Bridgewater [HQ]

Risk Factors

By Management
10-K
  1. Our competitors or other third parties may allege that we are infringing upon their IP, forcing us to expend substantial resources in litigation, the outcome of which is uncertain. Any unfavorable outcome of such litigation, including losses related to "at-risk" product launches, could have a material adverse effect on our business, financial position and results of operations.

  2. Our current operations in, and potential expansion into additional international markets subjects us to increased regulatory oversight both in those international markets and domestically as well as regulatory, economic, social and political uncertainties, which could cause a material adverse effect on our business, financial position and results of operations.

  3. Our reporting and payment obligations under the Medicaid rebate program and other governmental purchasing and rebate programs are complex and may involve subjective decisions. Any determination that we have failed to comply with those obligations could subject us to penalties and sanctions, which could have a material adverse effect on our business.

Get PRO Today.

Read 22 more risk factors of Amneal Pharmaceuticals, Inc.

End of AMRX's Analysis
CIK: 1723128 CUSIP: 03168L105 ISIN: US03168L1052 LEI: - UEI: -
Secondary Listings
AMRX has no secondary listings inside our databases.